# Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients

> **NCT04159818** · PHASE2 · RECRUITING · sponsor: **The Netherlands Cancer Institute** · enrollment: 52 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Cisplatin
- **DRUG:** Low dose doxorubicin

## Key facts

- **NCT ID:** NCT04159818
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-02-21
- **Primary completion:** 2022-12-15
- **Final completion:** 2026-12-15
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2022-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04159818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04159818, "Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04159818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*